摘要
China＇s ongoing investigation into GlaxoSmithKline and other global pharmaceutical Riants has sent out a clear and strong signal： Beijing is deter- mined to clamp down on any kind of cor- ruption. The closely-watched initiative could prompt multinational companies to beef up their compliance efforts in China and revise any procedures that may violate local rules and regulations, industry experts say.
